Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
Clinseq_AML
<p>This dataset is used in study "Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling". The original study is published on Leukemia (M Wang, J Lindberg, D Klevebring, C Nilsson, A S Mer, M Rantalainen, S Lehmann and H Grönberg. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia advance online publication 10 March 2017; doi: 10.1038/leu.2017.48).</p> <p> </p> <p>It includes demographic information, somatic mutations, normalized RNA sequencing counts, and derived prognostic scores of 274 patients diagnosed with acute myeloid leukemia. </p> <p> </p> <ul> <li>sex: Sex (M = male, F = female)</li> <li>age: Age at diagnosis</li> <li>aml_etiology: de novo = AML without any any antecedent causative disease or treatment, s-AML = AML following and antecedent hematological disorder such as MDS, MPN or aplastic anemia, t-AML = AML following radiation or cytotoxic drugs (patients treated with cytotoxic therapy for MDS/MPN are considered s-AML)</li> <li>OS: overall survival (days)</li> <li>status: Vital status (0 = alive, 1 = deceased)</li> <li>cytogenetic risk: cytogenetic risk classification</li> <li>ELN: the European LeukemiaNet (ELN) risk classification</li> <li>FLT3_ITD, DNMT3A, IDH1, IDH2_140, TET2, TP53, RUNX1, NRAS, CEBPA, WT1, KIT, ASXL1, PHF6, KRAS, PTEN, EZH2, PTPN11, U2AF1, SRSF2, SF3B1, STAG2, SMC1A, SMC3, RAD21, NPM1, IDH2_172, FLT3_HS, CEBPA2: somatic mutation (0 = wild type, 1 = mutated)</li> <li>ENSG***********: normalized RNA sequencing counts. Details about bioinformatics processing were described in Supplementary Methods of the publication.</li> <li>Derived prognostic scores: Details were described in the publication.</li> </ul> <p> </p> <p> </p>
Genome wide Illumina 450K array in AML patients with or without CEBPA mutation
<ul> <li>Num: Row Number</li> <li>Hybridization REF: CpG Reference ID</li> <li>Position: Position in hg19</li> <li>Gene: Entrez Gene Symbol</li> <li>Chrome: Chromosome Number</li> <li>p_vals: P value for t-test between patients with CEBPA and without CEBPA mutation</li> <li>mean_cebpa_mut: mean methylation score for patients with CEBPA mutation</li> <li>mean_no_cebpa_mut: mean methylation score for patients with CEBPA mutation </li> <li> <p>site_status: prediction status for CEBPA sites </p> </li> <li> <p>fdr: fdr p_value </p> </li> </ul>
scGeneAI AML dataset
<div>The input AML dataset used in the full-size examples in scGenAI is uploaded here</div> <div> <div> <p> </p> </div> </div>
Significance of the relationship between BIRC5 and the expression of other genes in AML patients
<p>BIRC5 expression levels were examined in relationship to the expression of other genes in the MILE dataset.</p>
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
ClinicalTrials.gov study NCT02323113. IPD Sharing: YES. Countries: 2. Publications: 1.
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT01349049. IPD Sharing: YES. Countries: 1. Publications: 1.
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT03552029. IPD Sharing: YES. Countries: 1. Publications: 1.
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
ClinicalTrials.gov study NCT01890746. IPD Sharing: UNDECIDED. Countries: 10. Publications: 1.
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT00989261. IPD Sharing: YES. Countries: 9. Publications: 1.
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT02668653. IPD Sharing: YES. Countries: 28. Publications: 4.
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT03512197. IPD Sharing: YES. Countries: 20. Publications: 0.
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
ClinicalTrials.gov study NCT04266795. IPD Sharing: YES. Countries: 5. Publications: 1.
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
ClinicalTrials.gov study NCT02039726. IPD Sharing: YES. Countries: 19. Publications: 3.
Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension
ClinicalTrials.gov study NCT00923091. IPD Sharing: YES. Countries: 15. Publications: 3.
Targeting autophagy: Polydatin's role in inducing cell death in AML
Open the record for dataset details and reuse information.
Constructing Lentiviral NSD3-Short-3xFLAG Constructs to Transduce AML Cell Lines
<p>SGC Open Lab Notebook Project - Understanding the Role of NSD3 in Cancer </p> <p>Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.</p>
Western Blotting NSD3 in AML Cell Lines
<p>SGC Open Lab Notebook Project - Understanding the Role of NSD3 in Cancer </p> <p>Experiment 011 - Western blot of MOLM-13, UCSD-AML1, and HL-60 AML cell lines probing for NSD3. </p>
CRISPR knockout of EZH1 in AML cell line
<p>We wanted to ensure the specificity of the EZH1 antibody that I was working with in previous posts, as well as creating a useful reagent to use in future experiments by generating a CRISPR knockout line of EZH1.</p>
Data for "Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed"
<p>This folder holds the data for the paper "Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed" (in submission) More information regarding this paper and the data is given in the GitHub repository (https://github.com/sgielis/WT1_TCR)</p> <p>The raw folder contains all MiXCR files for the two studied WT1 epitopes and two VZV epitopes. The VZV epitopes were not taken into account in this paper, but were used to build VZV-specific TCRex models for another paper [in submission]. Since all TCRs for the 4 epitopes were sequences together, this data was used for quality control purposes as explained in the paper. Following 4 folders are present:</p> <ul> <li>run1: TCR data from the first run for WT1-126, WT1-37 and IE62</li> <li>run1_orf18: TCR data from the first run for ORF18</li> <li>run2: WT1-37 data filtered on high and low threshold gating.</li> <li>run 3: extra TCR data for WT1-126, WT1-37 aligned with MiXCR</li> </ul> <p> </p>
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
ClinicalTrials.gov study NCT03727750. IPD Sharing: YES. Countries: 6. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.